Fulgent Genetics, Inc.
FLGTHealthcareNASDAQDiagnostics & Research · Last scanned May 30, 2026
Scan Results
Daily timeframeFulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. Valued at $515.2M, FLGT is a small-cap name in its sector. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
Market Cap
$515.2M
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
-11.87
EPS (TTM)
$-2.40
EPS (Fwd)
$-1.53
ROE
-6.9%
ROA
-5.4%
Cash
$276.3M
Total Debt
$10.2M
Free CF
-$105.9M
52W Change
-12.2%
Annual Financials
Cash vs Debt
With $276.3M in cash and $10.2M in debt, FLGT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$105.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -6.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $619.0M (2022) to $322.7M (2025), a 48% decline worth watching.
With cash comfortably exceeding debt, FLGT has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing FLGT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.